|
Basic Characteristics of Mutations
|
|
Mutation Site
|
N501Y |
|
Mutation Site Sentence
|
Importantly,LCB1v1.3 protected in vivo against a historical strain (WA1/2020),an emerging B.1.1.7 strain,and a strain encoding key E484K and N501Y spike protein substitutions. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
S |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
B.1.351;B.1.1.28;B.1.1.7 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cell line
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
34192518
|
|
Title
|
Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease
|
|
Author
|
Case JB,Chen RE,Cao L,Ying B,Winkler ES,Johnson M,Goreshnik I,Pham MN,Shrihari S,Kafai NM,Bailey AL,Xie X,Shi PY,Ravichandran R,Carter L,Stewart L,Baker D,Diamond MS
|
|
Journal
|
Cell host & microbe
|
|
Journal Info
|
2021 Jul 14;29(7):1151-1161
|
|
Abstract
|
Despite the introduction of public health measures and spike protein-based vaccines to mitigate the COVID-19 pandemic, SARS-CoV-2 infections and deaths continue to have a global impact. Previously, we used a structural design approach to develop picomolar range miniproteins targeting the SARS-CoV-2 spike receptor-binding domain. Here, we investigated the capacity of modified versions of one lead miniprotein, LCB1, to protect against SARS-CoV-2-mediated lung disease in mice. Systemic administration of LCB1-Fc reduced viral burden, diminished immune cell infiltration and inflammation, and completely prevented lung disease and pathology. A single intranasal dose of LCB1v1.3 reduced SARS-CoV-2 infection in the lung when given as many as 5 days before or 2 days after virus inoculation. Importantly, LCB1v1.3 protected in vivo against a historical strain (WA1/2020), an emerging B.1.1.7 strain, and a strain encoding key E484K and N501Y spike protein substitutions. These data support development of LCB1v1.3 for prevention or treatment of SARS-CoV-2 infection.
|
|
Sequence Data
|
-
|
|
|